AffaMed Therapeutics
Biotechnology ResearchShanghai, China11-50 Employees
AffaMed Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China, with 11-50 employees. It focuses on developing and commercializing pharmaceutical, digital and surgical products to address unmet medical needs in ophthalmic, neurological, and psychiatric disorders for patients in Greater China and worldwide. The leadership team has extensive experience in discovery, clinical development, regulatory affairs, manufacturing, commercial operations, and business development at multinational pharmaceutical companies. AffaMed has engaged in multiple licensing and collaboration arrangements, including a licensing agreement with Allgenesis Biotherapeutics for AG-73305 in Greater China, South Korea and ASEAN markets; licensing of EVOLUX intraocular lens; partnerships related to digital therapies with Beijing Tiantan Hospital and IBT; a DEXTENZA licensing arrangement with Ocular Therapeutix; a commercialization rights agreement with Eli Lilly for Galcanezumab in Mainland China; and a collaboration with VistaGen for PH94B in China, South Korea and Southeast Asia. The company employs a technology stack that includes Amazon Web Services, Microsoft Azure, Kubernetes, npm, TypeScript, and Microsoft Office applications such as Word and PowerPoint.
1-888-653-2347 
support@leadiq.com 
